Repron provides treatments for solid tumour cases where radical excision is not possible and metastasis or recurrence is extremely likely.
Repron Therapeutics has raised $2.1M in total funding. The most recent round was Seed. The last funding was announced in June 2023.
Repron Therapeutics's investors include Claris Ventures.
Repron Therapeutics is headquartered in Milano, Italy.
Repron provides treatments for solid tumour cases where radical excision is not possible and metastasis or recurrence is extremely likely.
Repron Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Repron Therapeutics — Funding & Investors." VCBacked, June 6, 2023, https://www.vcbacked.co/company/repron-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). Repron Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/repron-therapeutics
{{cite web |title=Repron Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/repron-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated